Table 2.

Summary of the studies targeting astrocytes to improve remyelination.

Disease Model	Treatment	Mechanism of Action	Outcomes	Reference
MS (LPC)	Intracellular sigma peptide	Inhibition of protein tyrosine phosphatase-sigma (PTPσ)	Decreased demyelination and astrogliosis Increased remyelination and functional recovery in the optic pathway.	[104]
MS (TMEV)	UCM03025	Inhibition of monoacylglycerol lipase (MagL)	Reduction in microglia activation, astrogliosis and CSPG levels around demyelinated lesions. Improvement in remyelination and motor functions.	[105]
SCI	Neuregulin1	PI3K-AKT-mTOR pathway	Reduction in astrogliosis. Enhancement of remyelination, axonal preservation and locomotor recovery.	[108]
SCI	SOX2	-	Reduction in glial scar volume. Increased neurogenesis and improvement in motor functions.	[109]
SCI	SOX10	Activation of EGF signalling	Increased generation of oligodendrocytes.	[113]